Vaprisol Related Published Studies
Well-designed clinical trials related to Vaprisol (Conivaptan Conjunctival)
Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers. [2007.03]
Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. [2007]
Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. [2006.06]
Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. [2001.11.13]
Well-designed clinical trials possibly related to Vaprisol (Conivaptan Conjunctival)
Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. [2003.01]
Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. [1999.11]
Other research related to Vaprisol (Conivaptan Conjunctival)
Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. [2008.10]
Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH. [2008.08]
Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. [2008.07]
Conivaptan: potential therapeutic implications in heart failure. [2008.06]
Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolemic hyponatremia: subgroup analysis of a randomized, controlled study. [2007.11.22]
Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. [2007.09]
Assessment of the Efficacy and Safety of Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia. [2007.07.26]
Conivaptan: new treatment for hyponatremia. [2007.07.01]
A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). [2007.01]
Conivaptan: a selective vasopressin antagonist. [2006.06]
Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. [2006.01]
Conivaptan Yamanouchi. [2005.03]
Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. [2005.01.10]
Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. [2003.06]
Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs. [2002.11]
Conivaptan (Yamanouchi). [2002.01]
[Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist] [1999.10]
Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. [1999.07.09]
Other possibly related research studies
Management of hyponatremia and clinical use of vasopressin antagonists. [2007.02]
New drugs 07, part I. [2007.02]
[Arginine vasopressin antagonism--new treatment option in chronic heart failure] [2007.01.18]
Hyponatremia in cirrhosis: clinical features and management. [2006.10]
AVP receptor antagonists as aquaretics: review and assessment of clinical data. [2006.09]
Excipient hydrolysis and ester formation increase pH in a parenteral solution over aging. [2006.11.15]
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. [2006.07]
Vasopressin antagonists. [2006.08]
Vaptans and the treatment of water-retaining disorders. [2006.05]
Vasopressin receptor antagonists. [2006.06]
Vasopressin excess and hyponatremia. [2006.05]
Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents. [2006.04]
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. [2006.01]
Vasopressin antagonists in heart failure. [2004.12]
Vasopressin receptor antagonists in heart failure. [2003.12]
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. [2003.07]
[Treatment of heart failure: an update] [2002.07]
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. [2002.04]
[Recent progress of vasopressin research in cardiovascular diseases] [2007.06]
Recognition and treatment of hyponatremia in acutely ill hospitalized patients. [2007.02]
Therapeutic potential of vasopressin receptor antagonists. [2007]
Hyponatremia: clinical diagnosis and management. [2007.08]
[Vasopressin antagonists in treatment of hyponatremia] [2007.08]
Current issues for nurse practitioners: Hyponatremia. [2007.11]
Hyponatremia and vasopressin antagonism in congestive heart failure. [2007.11]
Non-peptide arginine-vasopressin antagonists: the vaptans. [2008.05.10]
Vasopressin-receptor antagonists in heart failure. [2008.05.01]
Hyponatremia in psychiatric patients: update on evaluation and management. [2008.01]
Gateways to clinical trials. [2007.09]
Water in health and disease: new aspects of disturbances in water metabolism. [2007.10]
Cerebral correlates of hyponatremia. [2007]
New agents for managing hyponatremia in hospitalized patients. [2007.02.01]
[Pharmacology and clinical relevance of vasopressin antagonists] [2008.05]
The management of ascites and hyponatremia in cirrhosis. [2008.02]
|
